
Coronavirus Facts and Myth Buster
With inputs from Dr Monica Vasudev US FDA cautions about antibody tests to assess immunity among the vaccinated In a safety communication, the US FDA …Read more
With inputs from Dr Monica Vasudev US FDA cautions about antibody tests to assess immunity among the vaccinated In a safety communication, the US FDA …Read more
CMAAO: In susceptible high-risk (pro-inflammatory and/or pro-coagulative) individuals, reactogenic vaccines can trigger transient thrombo-inflammation lasting first few (up to four) days. COVID Vaccine: non-replicative, non-repetitive …Read more
Sotrovimab, a monoclonal antibody has been accorded emergency use authorisation (EUA) by the US FDA for use in patients aged 12 years and older with …Read more
CMAAO: In susceptible high-risk (pro-inflammatory and/or pro-coagulative) individuals, reactogenic vaccines can trigger transient thrombo-inflammation lasting first few (up to four) days. COVID Vaccine: non-replicative, non-repetitive …Read more
A systematic review was conducted to analyse the characteristics of patients with Covid-19 infection, who also had developed mucormycosis, and their outcomes. This review also …Read more
CMAAO: In susceptible high-risk (pro-inflammatory and/or pro-coagulative) individuals, reactogenic vaccines can trigger transient thrombo-inflammation lasting first few (up to four) days. COVID Vaccine: non-replicative, non-repetitive …Read more
Stroke due to cerebral sinus thrombosis as a presenting feature of vaccine-induced thrombosis and thrombocytopenia (VITT) has been frequently reported earlier. However, ischemic stroke due …Read more
CMAAO: In susceptible high-risk (pro-inflammatory and/or pro-coagulative) individuals, reactogenic vaccines can trigger transient thrombo-inflammation lasting first few (up to four) days. COVID Vaccine: non-replicative, non-repetitive …Read more
Pfizer and AstraZeneca Covid-19 vaccines are effective against symptomatic disease due to the B.1.617.2 variant detected in India, according to a new study conducted by …Read more
CMAAO: In susceptible high-risk (pro-inflammatory and/or pro-coagulative) individuals, reactogenic vaccines can trigger transient thrombo-inflammation lasting first few (up to four) days. COVID Vaccine: non-replicative, non-repetitive …Read more
Copyright © 2022 | All Rights Reserved. | Powered by Dr K K Aggarwal